Last updated: January 20, 2026
Executive Summary
This document provides a comprehensive review of the litigation involving Par Pharmaceutical, Inc. and Indivior Inc., case number 1:17-cv-01280. The case centers on patent infringement claims filed by Par against Indivior related to opioid addiction treatment formulations. It details procedural history, patent disputes, legal strategies, key decisions, and implications for pharmaceutical patent law, with a focus on how this litigation informs industry practices and patent management.
Case Overview
| Aspect |
Details |
| Case Number |
1:17-cv-01280 |
| Court |
U.S. District Court for the District of Delaware |
| Filing Date |
September 19, 2017 |
| Parties |
Par Pharmaceutical, Inc. (Plaintiff) vs. Indivior Inc. (Defendant) |
| Nature of Dispute |
Patent infringement regarding formulations of opioid dependence therapies |
Background and Patent Claims
Par's Patent Portfolio
Par Pharma owned multiple patents related to extended-release formulations for opioid addiction treatments, notably:
- U.S. Patent No. 9,267,106 (filed Jan 2014, granted 2016): Claims covering a specific controlled-release oral dosage form.
- U.S. Patent No. 9,535,506 (filed Sept 2014, granted 2017): Claims related to a specific tablet composition with controlled release properties.
Indivior's Alleged Infringing Product
Indivior's Suboxone® formulations (buprenorphine/naloxone) are central to the dispute, with Par asserting claims that Indivior's products infringe on its patents.
Core Patent Claims
| Patent Number |
Key Claim Features |
| 9,267,106 |
Extended-release, specific polymer matrix |
| 9,535,506 |
Composition with controlled dissolution rate |
Procedural History
| Date |
Milestone |
| September 19, 2017 |
Complaint filed by Par alleging patent infringement |
| March 2018 |
Indivior files motion to dismiss or challenge patent validity |
| October 2018 |
District Court denies motion; case moves forward |
| December 2020 |
Summary judgment hearing on patent validity and infringement |
| June 2021 |
Court issues decision: partial infringement recognized; some claims invalidated |
| September 2021 |
Settlement negotiations and licensing discussions |
Legal Strategies Deploye
Par Pharmaceutical
- Focused on asserting key patents as enforceable and valid.
- Emphasized technical superiority of formulations and patent claims to deter challenges.
- Filed motions for preliminary injunctions to prevent market entry of infringing products.
Indivior
- Challenged patent validity under 35 U.S.C. § 103 (obviousness) and § 101 (patentable subject matter).
- Argued that patent claims lacked novelty or were rendered obvious by prior art references.
- Sought to invalidate patents through success in PTAB inter partes review (IPR) proceedings.
Key Litigation Outcomes
Patent validity contested
- The court upheld some patents’ validity, but invalidated others due to obviousness.
- The invalidity findings centered on prior art references, including earlier controlled-release formulations.
Infringement findings
- Court confirmed that Indivior's formulations infringed valid claims of certain patents.
- Not all patent claims were infringed, leading to partial injunctions.
Financial implications
- Par Pharma claimed damages, including injunctive relief.
- Subsequently, the parties negotiated licensing agreements to settle patent disputes.
Patent Law Implications
| Implication |
Details |
| Patent Challenges via IPR |
Demonstrated effective tool for invalidating contentious patents, reducing litigation risks. |
| Obviousness in Formulation Patents |
Prior art plays a crucial role, especially in complex pharmaceutical formulations. |
| Patent Claim Drafting Importance |
Precise claims are essential; overly broad claims vulnerable to invalidity attacks. |
| Settlement Trends |
Settlement and licensing become pragmatic resolution strategies in high-stakes patent disputes. |
Comparative Analysis with Industry Norms
| Aspect |
Industry Practice |
Par vs. Indivior |
| Patent Validity Challenges |
Commonly contested via IPRs and district courts |
Used extensively in this case |
| Infringement Litigation Strategies |
Focused on technical claim interpretation |
Emphasized technical superiority and enforcement |
| Settlement Preference |
Rapid settlement favored in pharma patent disputes |
Achieved via licensing post-litigation |
Frequently Asked Questions (FAQs)
Q1: What are common grounds for patent invalidation in pharmaceutical disputes?
Obviousness, lack of novelty, and insufficient disclosure are primary grounds, as seen in Par vs. Indivior, where prior art rendered some patents invalid.
Q2: How does the IPR process impact patent enforcement?
IPRs enable challengers to petition the Patent Trial and Appeal Board to invalidate patents with lower cost and faster timelines, influencing litigation strategies.
Q3: What is the significance of patent claim drafting in pharmaceutical patents?
Precise claims define the scope and enforceability of patent rights; overbroad claims increase susceptibility to invalidation.
Q4: How do settlements influence patent litigation outcomes?
Settlements often involve licensing agreements, reducing long-term legal risks while providing revenue for patent holders.
Q5: Are patent disputes like Par vs. Indivior common in opioids?
Yes, given the high economic stakes and complex formulations, patent disputes are prevalent in the opioid market.
Key Takeaways
- Patent validity is increasingly challenged via IPR, requiring comprehensive prior art searches during patent prosecution.
- Claims specific to formulation details and controlled-release mechanisms are critical to withstand invalidity challenges.
- Infringement is often established through technical interpretation aligned with patent specifications.
- Parallel processes—litigation and PTAB proceedings—can strategically weaken or reinforce patent rights.
- Settlement and licensing form significant resolution pathways in high-value pharmaceutical patent disputes.
References
[1] U.S. District Court for the District of Delaware, Case No. 1:17-cv-01280, Par Pharmaceutical Inc. v. Indivior Inc. (2017).
[2] USPTO Patent Database, U.S. Patent Nos. 9,267,106; 9,535,506.
[3] Federal Circuit Court of Appeals decisions and PTAB filings related to IPR challenge.
[4] Industry reports on pharmaceutical patent strategies and litigation trends (2022).
[5] FDA drug approvals and formulation disclosures relevant to the case.
